Elevra Lithium Announces Accelerated NAL Expansion
Rhea-AI Summary
Elevra Lithium (NASDAQ:ELVR) announced an accelerated, staged expansion of the North American Lithium (NAL) site that uses new permitting information plus existing permits to fast-track production and lower unit costs. Key milestones: an initial 15–20% production uplift above current levels starting mid-CY27, further milling expansion to 6,500 tpd to target 315 ktpa spodumene by early CY28 using a temporary mobile crusher, and final replacement with a new crushing and ore-sorting circuit by early CY29. C1 unit cash costs were revised to US$630/t (previously US$562/t); AISC remains US$680/t. Reported project economics remain: NPV ≈ US$950M and IRR 26.4%. An updated scoping study and detailed engineering are planned for Q2 CY26.
Positive
- Brings forward incremental production by approximately two years
- Initial 15–20% spodumene output increase starting mid-CY27
- Staged path reduces initial upfront capital requirements
- Maintains reported project NPV of ≈US$950M and IRR of 26.4%
- AISC unchanged at US$680 per tonne after reallocation
Negative
- Revised C1 LOM unit cash cost increased to US$630 per tonne (from US$562)
- Final production ramp to 315ktpa now staged across CY27–CY29, extending execution timeline
- Key metrics pending updated scoping study and detailed engineering in Q2 CY26
Key Figures
Market Reality Check
Peers on Argus
ELVR was nearly flat (-0.24%) while key peers showed mixed moves: some up (e.g., WRN, NAK), some down (e.g., NB, LZM), and TMQ unchanged, suggesting stock-specific factors rather than a unified sector move.
Market Pulse Summary
This announcement outlines a staged debottlenecking plan to lift NAL output to a life-of-mine average of 315ktpa, bringing forward incremental production by about two years and spreading capital over time. The company also corrected C1 costing, raising post-expansion C1 to US$630/t while keeping AISC at US$680/t. Key project metrics, including NPV of US$950M and 26.4% IRR, remain unchanged. Investors may watch the Q2 CY26 updated scoping study for detailed cost and timing breakdowns of each debottlenecking phase.
Key Terms
spodumene concentrate technical
life of mine technical
C1 unit cash costs financial
all-in sustaining costs financial
AISC financial
NPV financial
IRR financial
scoping study technical
AI-generated analysis. Not financial advice.
BRISBANE, Australia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra” or “Company”) (ASX:ELV; NASDAQ:ELVR; OTCQB:SYAXF) advises that further refinement of the NAL mine expansion program has identified a pathway to stage permitting, construction and capital investment to fast-track additional production with lower unit operating costs.
Elevra previously outlined a whole-of-project expansion that would increase spodumene concentrate production to 315ktpa, with construction to be completed by the end of CY29 and commissioning thereafter1. The critical path constraint on this schedule was permitting. As such, recent efforts have focussed on determining steps and an approach to reduce this constraint.
By making use of additional permitting information received following the publication of the scoping study, Elevra has identified a project development sequence that provides a shorter timeframe to achieve increased production from NAL. The additional new permitting information, combined with existing permits, provides a pathway to stage the expansion of production volumes at NAL in a disciplined, agile and more time efficient manner.
The expansion pathway is now proposed take the form of a series of debottlenecking steps which are expected to:
- Increase production capacity above current levels in a staged and incremental manner;
- Reduce the timeframe to achieve the expanded average Life of Mine (LOM) production volume of 315ktpa of spodumene concentrate; and
- Enable the capital investment to be staged and, in doing so, reduce the initial upfront capital requirements.
The debottlenecking steps are anticipated to be delivered as below:
- An initial 15
-20% increase in annual spodumene concentrate production above current production levels commencing in mid-CY27 with an incremental reduction in unit operating costs. This increase is within the current limits of the milling permit, which is set at 4,500 tonnes per day (tpd); - A subsequent expansion of downstream milling, flotation and filtration capacity to 6,500 tpd with an anticipated corresponding concentrate production rate of 315ktpa. The incremental feed material will be processed using a temporary mobile crushing circuit operating in conjunction with the existing crushing circuit. The further expanded production is expected to commence early CY28, with an additional incremental reduction in unit operating costs; and
- The replacement of the temporary mobile crushing circuit and the existing crushing circuit with a new crushing and ore sorting circuit capable of meeting feed requirements for a LOM average production of 315ktpa. This final step is expected to be completed in early CY29 and is expected to deliver crushing and ore sorting cost efficiencies required to meet the anticipated LOM cost reduction.
This staged development strategy is anticipated to bring forward incremental production by approximately two years compared with previous plans, while also spreading capital expenditure over a longer period.
Given the low risk, brownfield nature of the proposed expansion, the Company plans to provide an updated scoping study in the first part of Q2 CY26. In conjunction with updating the scoping study, the Company plans to move directly to detailed engineering to advance the respective debottlenecking steps. The updated scoping study will provide a breakdown of operating and capital costs associated with the debottlenecking phases described above.
Commenting on the improved production plan, Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “We have taken a disciplined and pragmatic approach to accelerating production growth at North American Lithium, and the result is a materially improved development pathway. By leveraging new permitting information received since the scoping study, together with permits already in place, we have identified a staged expansion sequence that removes permitting from the critical path and brings forward incremental production in a low-risk, brownfields setting, while maintaining a clear pathway to 315ktpa of spodumene concentrate.”
“The revised strategy is expected to deliver production growth through targeted, capital-efficient debottlenecking steps, bringing forward increased output by approximately two years while spreading capital investment over time and capturing economies of scale. Given the robust nature of the asset and the reduced execution risk, we will update the scoping study and move directly into detailed engineering, providing greater cost clarity and accelerating value creation at NAL.”
During completion of the review of the scoping study2, it was identified that previously reported C1 unit cash costs did not correctly allocate site SG&A costs. Following reallocation, forecast post-expansion C1 LOM unit cash costs are US
However, all-in sustaining costs (“AISC”) as detailed in the scoping study2 remain unchanged at US
Announcement authorised for release by Elevra’s Managing Director and Chief Executive Officer.
About Elevra Lithium
Elevra Lithium Limited is a North American lithium producer (ASX:ELV; NASDAQ:ELVR; OTCQB:SYAXF) with projects in Québec, Canada, United States, Ghana and Western Australia.
In Québec, Elevra’s assets comprise North American Lithium (
In Western Australia, the Company holds a large tenement portfolio in the Pilbara region prospective for gold and lithium.
For more information, please visit us at www.elevra.com
1 See “NAL Expansion Scoping Study Confirms Lower Costs and Strong Returns” announcement filed with the ASX on 15 September 2025.
2 See “NAL Expansion Scoping Study Confirms Lower Costs and Strong Returns” announcement filed with the ASX on 15 September 2025. All figures reported at CAD/USD = 0.74 per Scoping Study results.

For more information, please contact: Andrew Barber Investor Relations PH: +61 7 3369 7058